What is Precipio, Inc.'s market cap?

Precipio, Inc. (PRPO) has a market capitalization of $47.7M and trades on NASDAQ.

Who are Precipio, Inc.'s competitors?

Precipio, Inc.'s key competitors include NeoGenomics, Labcorp, Quest Diagnostics, and others. These companies compete in similar markets and product categories.

Where is Precipio, Inc. headquartered?

Precipio, Inc. is headquartered in United States of America and employs approximately 57 people. It has been publicly traded since 2000.

Precipio, Inc. (PRPO) Stock Fundamentals & Financials

Precipio is a healthcare biotechnology company dedicated to improving the accuracy and accessibility of cancer diagnostics, with a primary focus on hematologic malignancies.

Market cap

$47.73M+67.9%

Earnings

Q2 2026 report

August 14, 2026

Revenue$7.0MBeat by $5.3M EPS-$0.12Beat by $1.88

Read the full report

Next report

Nov 16, 2026 (in 2 months)

Revenue estimate$1.7M

EPS estimate-$2.00

Competitors

By market cap

Quest Diagnostics$27.3B+33.8%

Labcorp Holdings$26.3B+14.7%

Guardant Health$23.5B+229%

NeoGenomics$2.4B+132%

Fulgent Genetics, Inc.$595.2M-11.7%

Precipio, Inc.$47.7M+67.9%

ADV

Advanced Biomed Inc.$12.8M+4.7%

ONC

Onconetix, Inc.$2.9M-40.4%

By revenue growth

Guardant Health+39.6%

NeoGenomics+11.2%

Quest Diagnostics+9.9%

Fulgent Genetics, Inc.+9.5%

Labcorp Holdings+6.4%

By net margin

Quest Diagnostics9.19%+0.2pp

Labcorp Holdings6.99%+1.3pp

NeoGenomics-6.77%+8.3pp

Fulgent Genetics, Inc.-23.04%-9.1pp

Guardant Health-40.1%+13.7pp

Profile

Precipio is a healthcare biotechnology company dedicated to improving the accuracy and accessibility of cancer diagnostics, with a primary focus on hematologic malignancies. The company operates a unique integrated model where its clinical laboratory services serve as a self-funded R&D unit to develop and validate proprietary diagnostic products. This structure aims to solve the systemic problem of disease misdiagnosis by delivering high-quality, cost-effective testing solutions to the oncology market.

Competitive position

Precipio differentiates itself through an integrated clinical-lab-to-product-development model that reduces R&D costs and time-to-market for specialized oncology assays.

GeographiesUnited States

Customer segmentsHealthcare providers, Diagnostic laboratories, Oncology clinics

Business modelDirect-to-customer services, Product manufacturing and sales, Integrated R&D

SuppliersLaboratory equipment manufacturers, Reagent suppliers, Logistics and courier services for specimen transport

CustomersOncology patients, Health insurance providers, Medicare and Medicaid, Third-party clinical laboratories

CountryUnited States of America

Listed2000

Employees57.0

CEOIlan Danieli

SectorHealthcare

IndustryMedical - Diagnostics & Research

Websiteprecipiodx.com

FilingsSEC EDGAR

FAQ

What is Precipio, Inc.'s market cap?: Precipio, Inc. (PRPO) has a market capitalization of $47.7M and trades on NASDAQ.
Who are Precipio, Inc.'s competitors?: Precipio, Inc.'s key competitors include NeoGenomics, Labcorp, Quest Diagnostics, and others. These companies compete in similar markets and product categories.
Where is Precipio, Inc. headquartered?: Precipio, Inc. is headquartered in United States of America and employs approximately 57 people. It has been publicly traded since 2000.